One of the compounds, PROTAC 38 (Table 1), effectively induced ALK degradation and inhibited the growth of the ALK fusion-positive cell line SU-DHL-1 and the human NSCLC cell line H3122, and also inhibited tumor growth in the H3122 xenograft model [68]. Here, ALK is linked to neoplasm.